Physician profile
Coby Thomas Brown
NPI 1083907059
$1,969.94
in general payments reported to CMS, 2019-2025
27 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $199 · 2021: $374 · 2022: $325 · 2023: $300 · 2024: $331 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $328.29 | 2021-2025 | Vistaseal, Stratafix, Dermabond Prineo |
| Abbvie INC. | $280.87 | 2019-2024 | Orilissa |
| Boston Scientific Corporation | $272.03 | 2019-2021 | |
| Hologic Sales and Service, LLC | $166.08 | 2021-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Organon LLC | $120.54 | 2022-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $98.23 | 2022-2025 | |
| Biogen, INC. | $79.52 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $72.01 | 2022-2025 | Injectafer |
| Medical Device Business Services, INC. | $52.20 | 2021 | |
| Evofem Biosciences, INC. | $50.04 | 2021-2022 | |
| Femselect INC. | $46.78 | 2023 | Enplace |
| Genmab U.S., INC. | $44.16 | 2023 | Tivdak |
| Sumitomo Pharma America, INC. | $43.75 | 2023-2024 | Myfembree |
| Applied Medical Resources Corporation | $41.47 | 2024 | |
| Exeltis, USA INC. | $39.92 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.62 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $32.41 | 2021 | |
| Therapeuticsmd, INC. | $31.21 | 2020-2022 | |
| Coloplast Corp | $26.41 | 2023 | Altis |
| Lupin INC. | $18.16 | 2020 | |
| Solventum Corporation | $15.54 | 2025 | Prevena |
| C. R. Bard, INC. & Subsidiaries | $14.75 | 2024 | Bd Onclarity |
| Octapharma USA, INC. | $13.82 | 2025 | Fibryga |
| Teleflex LLC | $13.19 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.38 | 2022 | |
| Tactile Systems Technology INC | $11.83 | 2020 | |
| Trevena, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coby Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.